CTLT - Cybin inks drug development agreement with Catalent

Cybin (CLXPF) has signed a drug development agreement with Catalent (CTLT) to gain access to its proprietary Zydis orally disintegrating tablet ((ODT)) technology for the delivery of Cybin's novel deuterated tryptamine ((CYB003)), a potential therapy for treatment-resistant psychiatric disorders.Zydis creates a freeze-dried tablet that disperses almost instantly in the mouth without water and is recognized as one of the world’s best-performing ODTs.Delivering CYB003 in such a dose form could have significant benefits, as an ODT would allow pre-gastric delivery and prevent first pass metabolism, potentially improving the pharmacokinetic profile of the drug.The project is due to commence in April 2021 and will involve initial feasibility studies being conducted for the manufacturing and analytical testing of ODT doses containing varying quantities of CYB003, alongside different excipients.

For further details see:

Cybin inks drug development agreement with Catalent